Caveolae and caveolin-3 in muscular dystrophy (Q33845396)

29 July 2017

1 reference

title

Caveolae and caveolin-3 in muscular dystrophy (English)

1 reference

29 July 2017

1 reference

Galbiati F

1

1 reference

29 July 2017

Razani B

series ordinal

2

1 reference

29 July 2017

Lisanti MP

series ordinal

3

1 reference

29 July 2017

publication date

1 October 2001

1 reference

Trends in Molecular Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

7

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

435-441

1 reference

Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin, a protein component of caveolae membrane coats

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin forms a hetero-oligomeric protein complex that interacts with an apical GPI-linked protein: implications for the biogenesis of caveolae

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Induction of caveolae in the apical plasma membrane of Madin-Darby canine kidney cells

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin-1 and -2 in the exocytic pathway of MDCK cells.

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Emerging themes in lipid rafts and caveolae.

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolins, a Family of Scaffolding Proteins for Organizing “Preassembled Signaling Complexes” at the Plasma Membrane

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Oligomeric structure of caveolin: implications for caveolae membrane organization

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Expression and Characterization of Recombinant Caveolin

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

VIP21/caveolin is a cholesterol-binding protein

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Evidence for a regulated interaction between heterotrimeric G proteins and caveolin

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Unexpectedly strong binding of a large metal ion (Bi3 ) to human serum transferrin

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Identification, sequence, and expression of caveolin-2 defines a caveolin gene family

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin is an activator of insulin receptor signaling

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Association of phosphofructokinase-M with caveolin-3 in differentiated skeletal myotubes. Dynamic regulation by extracellular glucose and intracellular metabolites

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin-3 associates with developing T-tubules during muscle differentiation

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Complementary distributions of vinculin and dystrophin define two distinct sarcolemma domains in smooth muscle

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family members

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin-3 is not an integral component of the dystrophin glycoprotein complex

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myot

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Increased caveolin-3 levels in mdx mouse muscles

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

The molecular basis of muscular dystrophy in the mdx mouse: a point mutation

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Limb-girdle muscular dystrophy (LGMD-1C) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-1C mutanta and rescues wild-type caveolin-3.

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin-3 in muscular dystrophy

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Mutations in the caveolin-3 gene: When are they pathogenic?

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Mutation in the CAV3 gene causes partial caveolin-3 deficiency and persistent elevated levels of serum creatine kinase

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin-3 deficiency causes muscle degeneration in mice

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade

1 reference

https://api.crossref.org/works/10.1016/S1471-4914(01)02105-0

7 January 2021

10.1016/S1471-4914(01)02105-0

Identifiers

DOI

1 reference

29 July 2017

1 reference